TY - JOUR
T1 - Prognostic value of the androgen receptor in addition to the established hormone receptors and HER2 status for predicting survival in women with early breast cancer
AU - Lokuhetty, Menaka Dilani S.
AU - Wijesinghe, Harshima D.
AU - Damen, Johanna A.A.G.
AU - Lee, Teresa
AU - White, Valerie A.
AU - Cree, Ian A.
AU - Indave, Blanca Iciar
N1 - Funding Information:
The authors would like to acknowledge the support and help from the Cochrane Breast Cancer Group for reviewing the protocol, especially Dr Rachel Dear (clinical editor, medical oncologist, The Kinghorn Cancer Centre, St Vincent's Hospital, Darlinghurst), Dr Fatima Cardoso (external clinical reviewer), Rebecca Seago-Coyle (consumer editor) and Sarah Hodgkinson (methods advisor, Editorial and Methods Department, Cochrane, London). Disclaimer The content of this article represents the personal views of the authors and does not necessarily represent the views of the authors? employers or associated institutions. Where authors are identified as personnel of the International Agency for Research on Cancer /World Health Organization, the authors alone are responsible for the views expressed in this article, and these views do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer / World Health Organization.
Publisher Copyright:
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020/11/16
Y1 - 2020/11/16
N2 - Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. Primary objectives The primary objective is to summarise available evidence on the overall prognostic value of androgen receptor (AR) expression, in addition to hormone receptors and HER2 status, for predicting survival in women with early breast cancer. Secondary objectives The secondary objectives are to evaluate disease-free survival, breast cancer-specific survival, and metastasis-free survival as prognostic outcomes.
AB - Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. Primary objectives The primary objective is to summarise available evidence on the overall prognostic value of androgen receptor (AR) expression, in addition to hormone receptors and HER2 status, for predicting survival in women with early breast cancer. Secondary objectives The secondary objectives are to evaluate disease-free survival, breast cancer-specific survival, and metastasis-free survival as prognostic outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85103014983&partnerID=8YFLogxK
U2 - 10.1002/14651858.CD013784
DO - 10.1002/14651858.CD013784
M3 - Article
AN - SCOPUS:85103014983
SN - 1465-1858
VL - 2020
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 11
M1 - CD013784
ER -